Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Conditions:   High Grade B-Cell Lymphoma, Not Otherwise Specified;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphom a;   Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements Interventions:   Drug: Bortezomib;   Biological: Rituximab;   Drug: Venetoclax Sponsors:   Rutgers, The State University of New Jersey;   National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.